Date & Time of Session - 10/19/26 - from 12:00 - 1:00 PM

Overview
This topic is highly clinically relevant as more bi specific T-cell engager (BiTE) therapies come to market and expand from primarily treating leukemias and lymphomas to treating solid tumors. Tarlatamab's FDA approval to treat small cell lung cancer in 2025 marked a huge step forward in BiTE's expansion; however, there are few studies that exist describing the implications of moving BiTE therapies to the outpatient cancer center setting. BiTE therapies carry unique risks, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which require step-up dosing, close patient monitoring, and coordination between inpatient and outpatient teams. As the use of BiTE therapies continues to expand beyond hematologic malignancies into solid tumors, it is important to better understand their real-world safety, effectiveness, and operational challenges. Evaluating these outcomes can help inform best practices and guide the safe implementation of these therapies in community oncology settings. 

Objectives
Upon completion of this activity, participants will be able to:
1. Describe the mechanism of action of tarlatamab and the role of DLL3-targeted bispecific T-cell engager (BiTE) therapy in the treatment of extensive-stage small cell lung cancer.
2. Differentiate the clinical presentation, grading, and pharmacologic and supportive management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) associated with tarlatamab therapy.
3. Compare the efficacy and safety outcomes reported in pivotal clinical trials with emerging real-world evidence evaluating tarlatamab use in community oncology practice.
4. Evaluate operational considerations for implementing outpatient BiTE therapy programs, including interdisciplinary coordination, toxicity monitoring, and opportunities for practice improvement within a community cancer center.

Target Audience
Free 1 credit hour of Continuing Education for St Elizabeth Health Care providers, Pharmacists, Residents and Students

Special Services
If you require special assistance to attend this event, please call Deanna Fliehman at (859) 301-6191

Speaker
Katie Reeder, PharmD
PGY1 Pharmacy Resident
St Elizabeth Healthcare - Edgewood, Kentucky

University of Kentucky is an Equal Opportunity Employer